Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and afatinib, are the first-line treatments for NSCLC patients harboring EGFR mutations3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.